Zanidatamab shows strong single-agent activity in HER2-positive gastric and biliary cancers

Zanidatamab, a dual HER2-binding antibody, demonstrated notable efficacy as a single agent in studies of gastric and biliary tract cancers.

The activity was described as striking, suggesting that targeting two HER2 epitopes may provide benefits beyond the conventional pertuzumab-trastuzumab combination.

These findings could influence future treatment strategies for HER2-positive gastro-esophageal and biliary malignancies, though further clinical evaluation is needed.